These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24907495)

  • 1. Comparing stimulant effects in youth with ADHD symptoms and epilepsy.
    Gonzalez-Heydrich J; Hsin O; Gumlak S; Kimball K; Rober A; Azeem MW; Hickory M; Mrakotsky C; Torres A; Mezzacappa E; Bourgeois B; Biederman J
    Epilepsy Behav; 2014 Jul; 36():102-7. PubMed ID: 24907495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy.
    Park J; Choi HW; Yum MS; Ko TS; Shon SH; Kim HW
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):537-546. PubMed ID: 30089215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit.
    Fosi T; Lax-Pericall MT; Scott RC; Neville BG; Aylett SE
    Epilepsia; 2013 Dec; 54(12):2071-81. PubMed ID: 24304474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate?
    Socanski D; Aurlien D; Herigstad A; Thomsen PH; Larsen TK
    Seizure; 2015 Feb; 25():80-3. PubMed ID: 25645642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial.
    van der Feltz-Cornelis CM; Aldenkamp AP
    Epilepsy Behav; 2006 May; 8(3):659-62. PubMed ID: 16504592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy.
    Baptista-Neto L; Dodds A; Rao S; Whitney J; Torres A; Gonzalez-Heydrich J
    Expert Opin Investig Drugs; 2008 Jan; 17(1):77-84. PubMed ID: 18095920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies.
    Santos K; Palmini A; Radziuk AL; Rotert R; Bastos F; Booij L; Fernandes BS
    Dev Med Child Neurol; 2013 Jul; 55(7):654-60. PubMed ID: 23480530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.
    Winters DE; Fukui S; Leibenluft E; Hulvershorn LA
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):298-305. PubMed ID: 29708762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: a Brazilian sample study and literature review.
    Koneski JA; Casella EB; Agertt F; Ferreira MG
    Epilepsy Behav; 2011 Jul; 21(3):228-32. PubMed ID: 21524941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities.
    Gucuyener K; Erdemoglu AK; Senol S; Serdaroglu A; Soysal S; Kockar AI
    J Child Neurol; 2003 Feb; 18(2):109-12. PubMed ID: 12693777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate for attention problems in epilepsy patients: Safety and efficacy.
    Leeman-Markowski BA; Adams J; Martin SP; Devinsky O; Meador KJ
    Epilepsy Behav; 2021 Feb; 115():107627. PubMed ID: 33360744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate, cognition, and epilepsy: A 1-month open-label trial.
    Adams J; Alipio-Jocson V; Inoyama K; Bartlett V; Sandhu S; Oso J; Barry JJ; Loring DW; Meador KJ
    Epilepsia; 2017 Dec; 58(12):2124-2132. PubMed ID: 28990169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate.
    Rheims S; Herbillon V; Villeneuve N; Auvin S; Napuri S; Cances C; Berquin P; Castelneau P; Nguyen The Tich S; Villega F; Isnard H; Nabbout R; Gaillard S; Mercier C; Kassai B; Arzimanoglou A;
    Epilepsia; 2016 Jul; 57(7):1069-77. PubMed ID: 27237724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy.
    Gonzalez-Heydrich J; Whitney J; Waber D; Forbes P; Hsin O; Faraone SV; Dodds A; Rao S; Mrakotsky C; Macmillan C; Demaso DR; de Moor C; Torres A; Bourgeois B; Biederman J
    Epilepsy Behav; 2010 Jul; 18(3):229-37. PubMed ID: 20493783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interactive effects of test-retest and methylphenidate administration on cognitive performance in youth with ADHD: A double-blind placebo-controlled crossover study.
    Horowitz I; Avirame K; Naim-Feil J; Rubinson M; Moses E; Gothelf D; Levit-Binnun N
    Psychiatry Res; 2020 Sep; 291():113056. PubMed ID: 32554183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.